An increasing amount of data suggests that such drugs and compounds acting on PPARγ-PGC-1α signaling may have beneficial effects in different brain diseases (Patrone et al., 2014; Carta and Simuni, 2015; Mäkelä et al., 2016b). The gene discussed is PPARGC1A; the disease is brain disorder.